Stellar Biotechnologies Announces Closing of Registered

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Stellar Biotechnologies Announces Closing of Registered Direct Offering

PORT HUENEME, CA--(Marketwired - Jul 6, 2016) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") ( NASDAQ : SBOT ), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), announced today that it has closed its previously announced $6.75 million sale of 1,687,500 common shares in a registered direct offering and unregistered warrants to purchase up to 1,265,626 unregistered common shares in a private placement. The combined purchase price for one registered common share and one unregistered warrant to purchase 0.75 of an unregistered common share was $4.00. The warrants have an exercise price of $4.50 per full share, are non-exercisable for 6 months and terminate 5 years from the time the warrants are first exercisable.

Maxim Group LLC acted as the sole placement agent for the offering.

Stellar intends to use the net proceeds from the offering for capital expenditures, research and development activities, operating costs and for general corporate purposes, including working capital.

"Stellar Biotechnologies is currently positioned to be a leading supplier of KLH protein for the exciting field of active immunotherapy. This financing from institutional investors will support important growth initiatives to meet demand anticipated from current and new customers as they advance through clinical development and prepare for commercial launch. This also strengthens our balance sheet and provides additional runway that will help our efforts to achieve future milestones," said Frank Oakes, President and CEO of Stellar Biotechnologies, Inc. "Our KLH products are already being used by our customers in multiple, clinical-stage programs and it is important that we are prepared to meet the demand from the pipeline of immunotherapies that will require a sustainable supply of the KLH protein."

The common shares were offered by Stellar pursuant to a shelf registration statement on Form S-3 (file no. 333-203595), which was declared effective on May 8, 2015 by the Securities and Exchange Commission (SEC). A final prospectus supplement and the accompanying prospectus relating to the offering of the common shares were filed with the SEC on June 30, 2016 and are available on the SEC's website at http://www.sec.gov . The warrants and the common shares issuable upon exercise of the warrants were offered in a separate private placement under Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act") and Regulation D Rule 506(c) and have not been registered under the Securities Act. The Company has agreed to file one or more registration statements with the SEC covering the resale of the common shares issuable upon exercise of the warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Stellar Biotechnologies

Stellar Biotechnologies, Inc. ( NASDAQ : SBOT ) is the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, immune disorders, Alzheimer's and inflammatory diseases) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

Visit www.stellarbiotech.com and the KLH knowledge base www.klhsite.org .

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not place undue reliance on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or future events to differ materially from the forward-looking statements. Such risks include, but may not be limited to: general economic and business conditions; technology changes; competition; changes in strategy or development plans; availability of funds and resources; governmental regulations and the ability or failure to comply with governmental regulations; the timing of the Company's or its partners' anticipated results, including in connection with clinical trials; the ability to meet the goals of the Company's joint ventures and strategic partnerships; and other factors referenced in the Company's filings with securities regulators. For a discussion of further risks and uncertainties related to the Company's business, please refer to the Company's public company reports filed with the B.C. Securities Commission and the U.S. Securities and Exchange Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements. This press release does not constitute an offer or solicitation of an offer for sale of any securities in any jurisdiction, including the United States.

Stellar Biotechnologies Company Contact: Mark A. McPartland Vice President of Corporate Development and Communications Phone: +1 (805) 488-2800 ext. 103 markmcp@stellarbiotech.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 290

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 169

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Target Kyverna Therapeutics: Key Details You Need

Updated Category News Views 136

Understanding Ongoing Investigations at Kyverna Therapeutics As the financial landscape continues to evolve, investors find themselves keenly interested in the developments surrounding Kyverna Therapeutics, Inc. (NASDAQ: KYTX). With a prominent law firm engaged in scrutinizing potential claims, the situation promises vital updates for concerned stakeholders. Faruqi &...

Continue Reading
Moody's Upgrades Phillips Edison to Baa2 Rating with Stability

Updated Category News Views 131

Moody's Upgrades Phillips Edison to Baa2 Rating CINCINNATI — Phillips Edison & Company, Inc. (Nasdaq: PECO), a prominent operator of high-quality grocery-anchored neighborhood shopping centers, has recently received an upgrade from Moody's Ratings. The company's issuer credit rating has been raised from 'Baa3' to 'Baa2', reflecting its strong operational performance and...

Continue Reading
Quantum Stocks Soar Amid Rumored Federal Investments

Updated Category News Views 222

Quantum Computing Stocks on the Rise Shares of IonQ Inc. (NYSE: IONQ), Rigetti Computing (NASDAQ: RGTI), and D-Wave Quantum (NYSE: QBTS) have experienced remarkable increases in pre-market trading. IonQ rose by 13.71%, Rigetti by 11.67%, and D-Wave surged by an impressive 15.90%. This surge comes as there are reports suggesting the federal government may be considering...

Continue Reading
Unlocking Success: How a One-Hour Morning Routine Can Transform Lives

Updated Category News Views 384

The Transformative Power of a Screen-Free Morning Jeff Bezos, the visionary behind Amazon, emphasizes the importance of a structured morning without distractions. His approach encourages starting the day without diving into screens, allowing for a calm and focused beginning. Understanding Bezos' Morning Ritual Instead of beginning his day with devices, Bezos opts for...

Continue Reading
Nokia's Strategic Moves: Infinera Acquisition and Stock Insights

Updated Category News Views 186

Nokia's Evolution in Telecom and Network Solutions Nokia Oyj is a global leader in telecom equipment and offers comprehensive network infrastructure solutions. While it once dominated the mobile phone market, Nokia has since repositioned itself as an essential player in the deployment and support of 5G and 4G networks. Its main competitor, Telefonaktiebolaget LM Ericsson,...

Continue Reading